Showing results (1-10 of 115) with videos related to
Sort By:
Pageof 12
British Journal of Clinical Pharmacology|October 29, 2019
Clinical trial simulations of the interaction between cannabidiol and clobazam and effect on drop-seizure frequencyKirsten Riber Bergmann, Karen Broekhuizen, Geert Jan GroeneveldDrug Discovery Today. Technologies|December 18, 2016
Measuring blood-brain barrier penetration using the NeuroCart, a CNS test batteryGeert Jan Groeneveld, Justin Luke Hay, Johannes Marinus Van GervenJournal of Visualized Experiments : Jove|May 12, 2016
Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task BatteryJustin L Hay, Pieter Okkerse, Guido van Amerongen, et al.Sensors (Basel, Switzerland)|March 28, 2024
Embedded Wireless Sensor for In Situ Concrete Internal Relative Humidity MonitoringTai Ikumi, Ignasi Cairó, Jan Groeneveld, et al.Alzheimer'S Research & Therapy|August 3, 2022
Inflammatory plasma biomarkers in subjects with preclinical Alzheimer's diseaseSamantha Prins, Marieke L de Kam, Charlotte E Teunissen, et al.Pain Medicine (Malden, Mass.)|February 5, 2021
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Pharmacodynamic Effects of VX-150, a Highly Selective NaV1.8 Inhibitor, in Healthy Male AdultsHemme J Hijma, Pieter S Siebenga, Marieke L de Kam, et al.British Journal of Clinical Pharmacology|May 21, 2016
A literature review on the pharmacological sensitivity of human evoked hyperalgesia pain modelsGuido van Amerongen, Matthijs W de Boer, Geert Jan Groeneveld, et al.Alzheimer'S Research & Therapy|July 18, 2021
A cross-sectional study in healthy elderly subjects aimed at development of an algorithm to increase identification of Alzheimer pathology for the purpose of clinical trial participationSamantha Prins, Ahnjili Zhuparris, Ellen P Hart, et al.International Journal of Molecular Sciences|February 10, 2021
Targeting for Success: Demonstrating Proof-of-Concept with Mechanistic Early Phase Clinical Pharmacology Studies for Disease-Modification in Neurodegenerative DisordersMaurits F J M Vissers, Jules A A C Heuberger, Geert Jan GroeneveldClinical and Translational Science|December 27, 2021
A phase I, randomized, double-blind, placebo-controlled, single- and multiple dose escalation study evaluating the safety, pharmacokinetics and pharmacodynamics of VX-128, a highly selective Nav 1.8 inhibitor, in healthy adultsHemme J Hijma, Emilie M J van Brummelen, Pieter S Siebenga, et al.Pageof 12